Other
Epiphora
8
Pipeline Programs↗
2
Active Trials↗
5
Companies Involved↗
Epiphora is an early-stage landscape with 8 programs across 5 companies. The most active players are Rehan Ahmed, Vitae Pharmaceuticals Inc., an Allergan affiliate, Revance Therapeutics, Inc.. 4 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 24
Phase 3
No programs
Analysis
Trial Status
6
clinical trials
Withdrawn2 · 33%
Completed2 · 33%
Active, not recruiting1 · 17%
Recruiting1 · 17%
Clinical Trials
Trial Activity
6 trials
A Randomized, Double-Masked, Dose-Ranging Study of Atropine Sulfate Ophthalmic Solution for the Treatment of Symptoms of Epiphora
Recruiting·—·Phase 2·NCT07676981·18 enrolled
Determination of the Optimum Delivery Route for Botulinum Toxin A in Patients With Epiphora
Completed·—·Phase 2·NCT01282541·26 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)